ZIOPHARM Oncology, Inc.Home | Contact Us | Sitemap
About UsClinical DevelopmentPartnershipsPatients/ProvidersInvestorsPress and Media




About Us




| About Us Home | Leadership Team | Board of Directors | Medical Advisory Board |
About UsRelated Links





ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of small molecule cancer drugs. The Company is currently focused on three clinical programs. 

Zymafos TM (palifosfamide, ZIO-201) is a novel molecule that is the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, ovarian, testicular and other cancers.  Palifosfamide delivers only the cancer fighting component of ifosfamide. It is expected to overcome the resistance of ifosfamide and cyclophosphamide in certain cancers. It does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of “fuzzy brain” (encephalopathy) and severe bladder inflammation. Intravenous (IV) palifosfamide is currently in a Phase II randomized trial to treat soft tissue sarcoma.  An oral form of palifosfamide has been developed preclinically and is expected to enter clinical study in 2009.

Zybulin TM (indibulin, ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration.  Indibulin is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity.  Indibulin will also be applicable to dose density mathematical modelingIndibulin has shown early activity in a Phase I study as a single agent in many types of solid tumors.  Indibulin is also currently in the Phase I portion of Phase I/II trials in combination with Tarceva® and Xeloda®.  Preclinical study continues with both dose density and metronomic administration.

Zinapar TM (darinaparsin, ZIO-101) is a novel organic arsenic being developed for the treatment of various hematologic and solid cancers. Preclinical and Phase I and II results to date demonstrate that darinaparsin is much less toxic than other forms of arsenic. Intravenous darinaparsin continues to be studied in a Phase II hematology trial showing activity in lymphomas and in Phase I study with oral administration.  Darinaparsin has been well tolerated in all trials to date.

ZIOPHARM’s operations are located in Boston, MA with an executive office in New York. 




Webcast Press Releases

August 4, 2010

ZIOPHARM Oncology to Present at the Canaccord Genuity 30th Annual Global Growth Conference More

July 30, 2010

ZIOPHARM Reports Second Quarter Financial Results and Updates Clinical Programs More




Video Media Coverage

Businessweek article
July 23, 2007 issue
More

Businessweek article
May 5, 2008 issue
More

Forbes.com article
May 9, 2008 issue
More

ZIO-101 listed as 100 Great Investigational Drugs by R&D Directions More

ZIO-201 listed as 100 Great Investigational Drugs by R&D Directions More




Webcast Events and Presentations

The Fifth Annual JMP Securities Healthcare Conference
September 27, 2010
Click Here for More Information

Canaccord 30th Annual Growth Conference
August 11, 2010
Click Here for More Information

ZIOPHARM Oncology Palifosfamide Trial Update
July 20, 2010
Click Here for More Information

Ziopharm Oncology highlighted on CBS Radio Network and WCBS-AM Health & Well Being Report
July 19, 2010
Click Here for More Information

ZIOPHARM Oncology's 2010 Annual Shareholder Meeting
June 23, 2010
Click Here for More Information

ZIOPHARM Oncology to Present at the Jefferies 2010 Global Life Sciences Conference
June 9, 2010
Click Here for More Information

ZIOPHARM Oncology to Present at the 9th Annual Needham Healthcare Conference
June 9, 2010
Click Here for More Information

ZIOPHARM Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference
May 17, 2010
Click Here for More Information

ZIOPHARM Oncology to Present at the Ninth Annual JMP Securities Research Conference
May 11, 2010
Click Here for More Information

ZIOPHARM Oncology to Present at the 22nd Annual Roth Growth Conference
March 15, 2010
Click Here for More Information




Stay Informed

Click to receive news alerts